Eric J. Hyllengren Sells 28,648 Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CFO Eric J. Hyllengren sold 28,648 shares of the firm’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $0.62, for a total value of $17,761.76. Following the completion of the sale, the chief financial officer now directly owns 645,671 shares of the company’s stock, valued at $400,316.02. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Atara Biotherapeutics Price Performance

Shares of ATRA opened at $0.69 on Wednesday. The firm has a market capitalization of $83.49 million, a price-to-earnings ratio of -0.33 and a beta of 0.70. Atara Biotherapeutics, Inc. has a 1-year low of $0.20 and a 1-year high of $2.54. The company has a 50-day moving average of $0.67 and a 200 day moving average of $0.67.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.14. The firm had revenue of $27.36 million during the quarter, compared to the consensus estimate of $27.00 million. Atara Biotherapeutics had a negative net margin of 671.70% and a negative return on equity of 783.31%. On average, equities analysts anticipate that Atara Biotherapeutics, Inc. will post -1.22 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Atara Biotherapeutics

Several institutional investors have recently bought and sold shares of ATRA. SG Americas Securities LLC purchased a new stake in shares of Atara Biotherapeutics during the 3rd quarter worth $57,000. Delap Wealth Advisory LLC bought a new position in Atara Biotherapeutics in the first quarter worth about $29,000. Vontobel Holding Ltd. purchased a new stake in shares of Atara Biotherapeutics during the fourth quarter valued at about $41,000. Private Advisor Group LLC boosted its holdings in shares of Atara Biotherapeutics by 53.0% in the 3rd quarter. Private Advisor Group LLC now owns 95,463 shares of the biotechnology company’s stock valued at $141,000 after buying an additional 33,063 shares in the last quarter. Finally, Josh Arnold Investment Consultant LLC boosted its holdings in shares of Atara Biotherapeutics by 17.6% in the 3rd quarter. Josh Arnold Investment Consultant LLC now owns 200,000 shares of the biotechnology company’s stock valued at $300,000 after buying an additional 30,000 shares in the last quarter. 70.90% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Friday, April 5th.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.